ASO Author Reflections: De-escalating Axillary Management in Women Over 70 with Hormone Receptor Positive Disease

Tonneson, Jennifer E.; Boughey, Judy C.

doi:10.1245/s10434-021-10492-2

Cited by 1 publication

(1 citation statement)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We opted to focus our efforts on surgeons themselves because evidence shows that surgeons, in this setting, serve as the therapeutic keystone by analyzing critical patient and tumor factors, facilitating multidisciplinary conversations with medical and radiation oncologists, and framing conversations on utility of SLNB with patients . While educational initiatives and nomogram-based risk calculators for predicting nodal positivity may help surgeons, our approach demonstrated a larger and more durable reduction in SLNB use because it was not a 1-time effort but a continuous, day-of-clinic-visit reminder present over 12 months.…”

Section: Discussionmentioning

confidence: 99%

Electronic Health Record–Based Nudge Intervention and Axillary Surgery in Older Women With Breast Cancer

Carleton,

Radomski,

et al. 2024

JAMA Surg

View full text Add to dashboard Cite

ImportanceChoosing Wisely recommendations advocate against routine use of axillary staging in older women with early-stage, clinically node-negative (cN0), hormone receptor–positive (HR+), and HER2-negative breast cancer. However, rates of sentinel lymph node biopsy (SLNB) in this population remain persistently high.ObjectiveTo evaluate whether an electronic health record (EHR)–based nudge intervention targeting surgeons in their first outpatient visit with patients meeting Choosing Wisely criteria decreases rates of SLNB.Design, Setting, and ParticipantsThis nonrandomized controlled trial was a hybrid type 1 effectiveness-implementation study with subsequent postintervention semistructured interviews and lasted from October 2021 to October 2023. Data came from EHRs at 8 outpatient clinics within an integrated health care system; participants included 7 breast surgical oncologists. Data were collected for female patients meeting Choosing Wisely criteria for omission of SLNB (aged ≥70 years with cT1 and cT2, cN0, HR+/HER2− breast cancer). The study included a 12-month preintervention control period; baseline surveys assessing perceived acceptability, appropriateness, and feasibility of the designed intervention; and a 12-month intervention period.InterventionA column nudge was embedded into the surgeon’s schedule in the EHR identifying patients meeting Choosing Wisely criteria for potential SLNB omission.Main Outcomes and MeasuresThe primary outcome was rate of SLNB following nudge deployment into the EHR.ResultsSimilar baseline demographic and tumor characteristics were observed before (control period, n = 194) and after (intervention period, n = 193) nudge deployment. Patients in both the control and intervention period had a median (IQR) age of 75 (72-79) years. Compared with the control period, unadjusted rates of SLNB decreased by 23.1 percentage points (46.9% SLNB rate prenudge to 23.8% after; 95% CI, −32.9 to −13.8) in the intervention period. An interrupted time series model showed a reduction in the rate of SLNB following nudge deployment (adjusted odds ratio, 0.26; 95% CI, 0.07 to 0.90; P = .03). The participating surgeons scored the intervention highly on acceptability, appropriateness, and feasibility. Dominant themes from semistructured interviews indicated that the intervention helped remind the surgeons of potential Choosing Wisely applicability without the need for additional clicks or actions on the day of the patient visit, which facilitated use.Conclusions and RelevanceThis study showed that a nudge intervention in the EHR significantly decreased low-value axillary surgery in older women with early-stage, cN0, HR+/HER2− breast cancer. This user-friendly and easily implementable EHR-based intervention could be a beneficial approach for decreasing low-value care in other practice settings or patient populations.Trial RegistrationClinicalTrials.gov Identifier: NCT06006910

show abstract

Section: Discussionmentioning

confidence: 99%